Relapse Clinical Trial
Official title:
"Comparative Evaluation of 3 Dimensional Changes of Dentition in Post Orthodontic Patients With Immediate vs Delayed (Post 7 Days) Retainer Delivery-A Randomized Control Trial"
After orthodontic treatment, relapse is inevitable and is defined as a movement towards the initial state which is undesirable. To prevent relapse, a phase of retention is required. Retention has been defined as "the holding of teeth following orthodontic treatment in the treated position for the period of time necessary for the maintenance of the result". Controversies regarding retention regime exist due to lack of high quality evidence regarding duration, type and timing of different type retainer. There is an unusual delay after debonding in retainer delivery as the retainer is fabricated at the laboratory. Such the present study will help us to find out within which time period the retainer should be delivered.
Status | Recruiting |
Enrollment | 40 |
Est. completion date | April 25, 2024 |
Est. primary completion date | December 25, 2023 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 45 Years |
Eligibility | Inclusion Criteria: - Adult orthodontic patients treated with 022*028 MBT appliance with following sequence of wires- 014, 016, 16*22, 17*25, 19*25 NiTi followed by 19*25 SS. - Treatment duration of 24-36 months with Optimal functional occlusion at end of treatment (PAR score >70%). - Class I bimax and Class II div I with pre-treatment Little's irregularity index <6mm in both upper and lower arch. - Nonsurgical and non-orthopedic patients. - Non syndromic patients and no impaction of teeth except third molars. - No previous orthodontic treatment. - Optimal periodontal condition and Good oral hygiene. - Good compliance regarding retainer wear (Cases who never missed more than 2 consecutive appointment and who reported with less no of breakages). Exclusion Criteria: - Subjects with incomplete orthodontic treatment. - TMJ disorder patients. - Any systemic disease affecting bone and general growth. - Patients with incomplete records. - Patient who fail to follow up or undergo complete treatment. - Patient with learning difficulties |
Country | Name | City | State |
---|---|---|---|
India | PGIDS | Rohtak | Haryana |
Lead Sponsor | Collaborator |
---|---|
Postgraduate Institute of Dental Sciences Rohtak |
India,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Overjet | sagittal distance between upper and lower incisors | T0 - baseline on the day of debonding | |
Primary | Overjet | sagittal distance between upper and lower incisors | T1 - 7 days after debonding | |
Primary | Overjet | sagittal distance between upper and lower incisors | T2 - 1 month after debonding | |
Primary | Overjet | sagittal distance between upper and lower incisors | T3 - 3 month after debonding | |
Primary | Overjet | sagittal distance between upper and lower incisors | T4 - 6 month after debonding | |
Primary | contact point displacement | displacement of contact points in anterior teeth | T0 - baseline on the day of debonding | |
Primary | contact point displacement | displacement of contact points in anterior teeth | T1 - 7 days after debonding | |
Primary | contact point displacement | displacement of contact points in anterior teeth | T2 - 1 month after debonding | |
Primary | contact point displacement | displacement of contact points in anterior teeth | T3 - 3 month after debonding | |
Primary | contact point displacement | displacement of contact points in anterior teeth | T4 - 6 month after debonding | |
Primary | overbite | vertical overlap of upper and lower incisors | T0 - baseline on the day of debonding | |
Primary | overbite | vertical overlap of upper and lower incisors | T1 - 7 days after debonding | |
Primary | overbite | vertical overlap of upper and lower incisors | T2 - 1 month after debonding | |
Primary | overbite | vertical overlap of upper and lower incisors | T3 - 3 month after debonding | |
Primary | overbite | vertical overlap of upper and lower incisors | T4 - 6 month after debonding | |
Primary | intermolar width | transverse distance between the first molars | T0 - baseline on the day of debonding | |
Primary | intermolar width | transverse distance between the first molars | T1 - 7 days after debonding | |
Primary | intermolar width | transverse distance between the first molars | T2 - 1 month after debonding | |
Primary | intermolar width | transverse distance between the first molars | T3 - 3 month after debonding | |
Primary | intermolar width | transverse distance between the first molars | T4 - 6 month after debonding | |
Primary | intercanine width | transverse distance between the canine | T0 - baseline on the day of debonding | |
Primary | intercanine width | transverse distance between the canine | T1 - 7 days after debonding | |
Primary | intercanine width | transverse distance between the canine | T2 - 1 month after debonding | |
Primary | intercanine width | transverse distance between the canine | T3 - 3 month after debonding | |
Primary | intercanine width | transverse distance between the canine | T4 - 6 month after debonding |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT04380220 -
Coagulation/Complement Activation and Cerebral Hypoperfusion in Relapsing-remitting Multiple Sclerosis
|
||
Completed |
NCT00306813 -
Evaluation of Lenalidomide, Doxorubicin and Dexamethasone (RAD) in Patients With Relapsed or Refractory Multiple Myeloma
|
Phase 1/Phase 2 | |
Completed |
NCT01956695 -
Efficacy of Lenalidomide With Rituximab in Refractory or Relapse of Primary Central Nervous System Lymphoma
|
Phase 2 | |
Not yet recruiting |
NCT05926167 -
Observational Trial Evaluating Elevated Factor VIII Related Labs as a Biomarker for Incomplete Relapse Recovery
|
||
Recruiting |
NCT03710512 -
Evaluation of Early Relapse After Mandibular Lengthening Surgery
|
||
Recruiting |
NCT04921540 -
Ingrown Toenails : Surgery Only Versus Surgery + Chemical Cauterization With TCA
|
N/A | |
Completed |
NCT05250765 -
Comparison of Efficiency and Effectiveness of Two Types of Bonded Orthodontic Retainers: an RCT.
|
N/A | |
Not yet recruiting |
NCT03830827 -
MBRP + Vortioxetine VS MBRP on Preventing Relapse in Chronic MA Users
|
Phase 4 | |
Completed |
NCT05915273 -
Relapse and Failure Rates Between CAD/CAM and Conventional Fixed Retainers
|
N/A | |
Active, not recruiting |
NCT04389879 -
CAD/CAM Fixed Retainers vs. Conventional Multistranded Fixed Retainers in Orthodontic Patients. Comparison of Stability, Retainer Failure Rate, Adverse Effects, Cost-effectiveness, and Patient Satisfaction. A Randomized Controlled Clinical Trial
|
N/A | |
Recruiting |
NCT06417359 -
Comparison of Mesh Fixation and Non-Fixation in eTEP
|
N/A | |
Recruiting |
NCT06417346 -
Comparison of Laparoscopic and Open Inguinal Hernia Repair in Elderly Patients
|
N/A | |
Completed |
NCT02145403 -
Phase 1/2 Study of Carfilzomib for the Prevention of Relapse and GVHD in Allo-HCT for Hematologic Malignancies
|
Phase 1/Phase 2 | |
Completed |
NCT01481701 -
A Trial Evaluating Efficacy and Safety of Oxaliplatin With 5-Fluorouracil in Patients With Recurrent Ovarian Carcinoma
|
Phase 2 | |
Recruiting |
NCT01941394 -
Mesenchymal Stem Cells Infusion for aGVHD Prophylaxis Transplantation
|
Phase 2 | |
Recruiting |
NCT04723901 -
Dual Target CAR-T Cells in B-cell Acute Lymphoblastic Leukemia
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT04994626 -
Ibrutinib Combined With Rituximab for Treatment of Relapsed Refractory MYD88 and CD79A/B (or CD79B Alone) DLBCL Who Have Received at Least Two Prior Therapies
|
Phase 2 | |
Recruiting |
NCT06292364 -
Comparison of Retention Characteristics of Immediate vs Delayed Retainer Delivery Using 3D Digital Model Analysis
|
N/A | |
Enrolling by invitation |
NCT05591703 -
Clinical Outcomes Following Transcutaneous Auricular Neurostimulation to Improve Relapse Prevention: A Long-term Follow-up Study
|
||
Active, not recruiting |
NCT00299923 -
Study for Patients With Chronic HCV (GT 1 or 3) Who Relapsed to Previous (Peg)Interferon/ Ribavirin Combination Therapy
|
Phase 3 |